References
- GBD. Lower respiratory infections collaborators, “Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016 (in eng). Lancet Infect Dis. 2016 Nov;18(11):1191–10. DOI:10.1016/s1473-3099(18)30310-4
- Donkor ES. Understanding the pneumococcus: transmission and evolution (in eng). Front Cell Infect Microbiol. 2013;3:7.
- Andrews EANJ. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808.
- Niederman MS, Folaranmi T, Buchwald UK, et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines. 2021;20(3):1–13.
- Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLOS Med. 2009 [May 26, 2009];6(5):e1000081. DOI:10.1371/journal.pmed.1000081.
- Statens Serum Institut. “Fakta om pneumokoksygdom og vaccination.” ssi.dk. [cited 2020 November 2]. Available from: https://www.ssi.dk/-/media/arkiv/dk/vaccination/risikogrupper/infografik-fakta-om-pneumokoksygdom-og-vaccination.pdf?la=da
- Fally M, Israelsen S, Anhøj J, et al. The increasing importance of Haemophilus influenzae in community-acquired pneumonia: results from a Danish cohort study (in eng). Infect Dis (Lond). 2021 Feb;53(2):122–130. 10.1080/23744235.2020.1846776.
- Djennad A, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6(101733727):42–50.
- European Centre for Disease Prevention and Control. Invasive pneumococcal disease - annual epidemiological report for 2018. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf
- Statens Serum Institut. Fakta om pneumokoksygdom og vaccination. [cited 2021 april 9]. Available from: https://www.ssi.dk/-/media/arkiv/dk/vaccination/risikogrupper/infografik-fakta-om-pneumokoksygdom-og-vaccination.pdf?la=da
- Sings HL. Pneumococcal conjugate vaccine use in adults – Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 2017;35:5406–5417.June. [Online]. Availablehttps://reader.elsevier.com/reader/sd/pii/S0264410X1730734X?token=9E2F3C10AF2207F95A30E226731ECAA7BC0692EA3EEBC2FE695B28852B0D497C5C20EC9A1E1D1DAA5038C07B8A633394&originRegion=eu-west-1&originCreation=20210915112149
- Statens Serum Institut. Personer med særlig risiko for invasiv pneumokoksygdom. cited 2021 April 10]. Available from: https://www.ssi.dk/vaccinationer/risikogrupper/invasiv-pneumokoksygdom
- Folkehelseinstituttet. Pneumokokkvaksine - veileder for helsepersonell. [cited 2021 April 9]. Available from: https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/pneumokokkvaksinasjon—veileder-fo/
- Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults. Am J Preventive Med. 2015December;49(6, 4):383–390. [Online]. Available. https://reader.elsevier.com/reader/sd/pii/S0749379715005474?token=88ECC1A7B6E6965D5B7329206C96C27821C8654771E8DD193C28C2BF702ADC524BC6C57E7E41138D81008055673D00EB&originRegion=eu-west-1&originCreation=20210915112448
- Norwegian Institute of Public Health. Pneumokokkvaksine - veileder for helsepersonell. [cited 2022 October 10]. Available from: https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/pneumokokkvaksinasjon—veileder-fo/?term=ppv23&h=1
- Statens Serum Institute. Invasive pneumococcal disease 2018-2019. https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/invasive-pneumococcal-disease-2018-2019
- Danish Health Authority. Tilbud om pneumokokvaccination til særlige risikogrupper. [cited 2022 October 10]. Available from: https://www.sst.dk/da/udgivelser/2020/rationel-farmakoterapi-6-2020/tilbud-om-pneumokokvaccination--til-saerlige-risikogrupper
- Løvlie A, Vestrheim DF, Aaberge IS, et al. Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13 (in eng). BMC Infect Dis. Jan 10 2020;20(1):29. DOI:10.1186/s12879-019-4754-0.
- Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance,” (in eng). Lancet Infect Dis. 2015 Mar;15(3):301–309. DOI: 10.1016/s1473-3099(14)71081-3.
- Izurieta P, Bahety P, Adegbola R, et al. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution,” (in eng). Expert Rev Vaccines. 2018 Jun;17(6):479–493. DOI:10.1080/14760584.2018.1413354.
- Gov.Canada. Pneumococcal vaccine: Canadian immunization guide. [citrd 2022 October 10]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a9
- Yamada M, Li M, Iino T. Pneumococcal vaccine coverage in Japan among patients with a history of splenectomy: results of a retrospective administrative database study,” (in eng). Vaccine. May 6 2021;39(19):2692–2697. DOI:10.1016/j.vaccine.2021.03.045
- Statens Serum Institut. Pneumokokvaccine 23-valent. [cited 2021 april 9]. Available from: https://www.ssi.dk/vaccinationer/vaccineleksikon/p/pneumokokvaccine-23-valent
- Gov. UK. Pneumococcal polysaccharide vaccine: patient group direction template. [cited 2022 October 10]. Available from: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-patient-group-direction-pgd-template
- Folkhalsomyndigheten. “Vaccin mot pneumokockinfektion.” [cited 2022 Octomber 12]. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/vacciner-a-o/pneumokocker/
- Center for Disease Control and Prevention. Evidence to Recommendations for PCV13 use among adults ≥65 years old. [cited 2022 October 12]. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/PCV13-etr.html
- Berild JD, Winje BA, Frimann Vestrheim D, et al. A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population. 2020. [April 3, 2020]. Pathogens. 9(4):259. DOI: 10.3390/pathogens9040259.
- Miller SA, Forrest JL. Enhancing your practice through evidence-based decision making: pICO, learning how to ask good questions. 2001. [2001 10 01]. J Evid Based Dent Pract. 1(2):136–141. DOI: 10.1016/S1532-3382(01)70024-3.
- Centers for Disease Control and Prevention (CDC). 2012. Principles of Epidemiology in Public Health Practice. https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section6.html.
- Wells GA, Shea B, Higgins JP, et al. Checklists of methodological issues for review authors to consider when including non-randomized studies in systematic reviews (in eng). Res Synth Methods. 2013 Mar;4(1):63–77. DOI:10.1002/jrsm.1077.
- Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine,” (in eng). N Engl J Med. Sep 4 1980;303(10):549–552. DOI:10.1056/nejm198009043031003.
- Kim JH, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. Vaccine. 2019;37(21):2797–2804.
- Leventer-Roberts, Leventer-Roberts M, Feldman BS, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015;60(10):1472–1480. DOI: 10.1093/cid/civ096.
- Gutierrez Rodriguez MA, Ordobás Gavín MA, García-Comas L, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. Euro Surveill. 2014;19(40):20922. DOI:10.2807/1560-7917.ES2014.19.40.20922
- Wright LB, Hughes GJ, Chapman KE, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012. Trials Vaccinol. 2013;2(1):45–48.
- Shimbashi R, Suzuki M, Chang B, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013–2017. Emerg Infect Dis. 2020;26(10):2378–2386.
- Tsai Y-H, Hsieh M-J, Chang C-J, et al. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—taiwan’s PPV vaccination program. Vaccine. 2015;33(25):2897–2902. DOI:10.1016/j.vaccine.2015.04.068.
- Bonten MJM, Huijts SM, Bolkenbaas M. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125.
- Moore MR, et al. Impact of 13-valent pneumococcal conjugate vaccine used in children on invasive pneumococcal disease in children and adults in the United States: analysis of multisite, population- based surveillance. Lancet Infect Dis. 2015 Mars;15(3):301–309. DOI:10.1016/S1473-3099(14)71081-3.
- Patterson S, Webber C, Patton M, et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Vaccinology 2016;5:92–96 [May 4, 2016].
- Clutterbuck EA, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells (in eng). J Infect Dis. May 1 2012;205(9):1408–1416. Doi:10.1093/infdis/jis212.
- Jackson LA, et al., “Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine,” Vaccine, vol. 31, no. 35, pp. 3585–3593, 2 August 2013. https://www.sciencedirect.com/science/article/pii/S0264410X13005884
- Rezai MS, Ghaffari J, Mahdavi M, et al. Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: a randomized clinical trial study. Caspian J Intern Med. 2017;8(1):16–22. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412244/pdf/cjim-8-016.pdf
- Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP) (in eng). MMWR Morb Mortal Wkly Rep. Oct 12 2012;61(40):816–819.